In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Orphazyme enters €9mm debt financing with Kreos Capital

Executive Summary

Rare disease-focused Orphazyme AS entered into a €9mm ($10mm) loan agreement with Kreos Capital. The structured debt facility has a term of 42 months and carries an annual fixed interest rate of 9.75%. The first 12 months are interest-only, while the remaining 30 months require equal installments of principal and interest. Orphazyme plans to draw down the loan on September 1, 2019. The company will use the funding to file for regulatory approvals (expected in H1 2020) of its arimoclomol for Niemann Pick Type-C in the US and Europe, and for commercial planning.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies